|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phosphorylated Akt and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab显示文摘 | Scartozzi M Giampieri R Maccaroni E | 2012 | J Transl Med2012，10，1： | 1 |
| 2 | COX -2 and NF- KB overexpression is common in pancreatic cancer but does not predict for COX -2 inhibitors activity in combination with gemcitabine and oxaliplatin显示文摘 | Cascinu S Scartozzi M Carbonari G | 2007 | Am J Clin Oncol2007，30，5： | 1 |
| 3 | Nuclear factor-KB tumor expression predicts response and survival in irinotecan-refractory metastatic eolorectal cancer treated with cetuximabirinotecan therapy 显示文摘 | SCARTOZZI M BEARZI I PIERANTONI C | 2007 | J Clin Oncol2007，25，25： | 1 |
| 4 | Chemotherapy for locally advanced and metastatic gastric cancer:state of the art and future perapectives显示文摘 | Bittoni A Maccaroni E Scartozzi M | 2010 | Eur Rev Med Pharmacol Sci2010，14，2： | 1 |
| 5 | Chemotherapy for advanced gastric cancer:across the year for a standard of care显示文摘 | Scartozzi M Galizla E Verdecchia L | 2007 | Expert Opin Pharmacother2007，8，6： | 1 |
| 6 | Trans-arteriai chemo-embolization (TACE),with either lipiodol (traditional TACE) ordrug-eluting microspheres ( precision TACE,pTACE ) in thetreatment of hepatocellular carcinoma : efficacy and safety resultsfrom a large mono-institutional analysis 显示文摘 | Scartozzi M Baroni GS Faloppi L | 2010 | J Exp Clin CancerRes2010，29，1： | 1 |
| 7 | High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)显示文摘 | Cascinu S Scartozzi M Labianca R | 2004 | Brit J Cancer2004，90，8： | 1 |
| 8 | Clinical predictive factors for advanced non-small cell lung cancer(NSCLC) patients receiving third-linetherapy:Seecting the unseleetable?显示文摘 | Scartozzi M Mazzanti P Giampieri R | 2010 | Lung Cancer2010，68，3： | 1 |
| 9 | Molecular biology ofsporadic gastric cancer: prognostic indicators and novel therapeuticapproaches 显示文摘 | Scartozzi M Galizia E Freddari F | 2004 | Cancer Treat Rev2004，30，5： | 1 |
| 10 | VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib:the ALICE-1study显示文摘 | Scartozzi M Faloppi L Svegliati Baroni G | 2014 | Int J Cancer2014，135，5： | 1 |
| 11 | The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management显示文摘 | Faloppi L Scartozzi M Bianconi M | 2014 | BMC Cancer2014，14，： | 1 |
| 12 | Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients显示文摘 | Scartozzi M Bearzi I Mandolesi A | 2011 | Br J Cancer2011，104，11： | 1 |
| 13 | High curativeresection rate with weekly cisplatin,5-fluorouracil,epidoxorubicin,6S-leucovorin,glutathione,and filgastrimin patients with locally advanced,unresectable gastric cancer:a report from the Italian Group for the Study of Digestive Tract C显示文摘 | Cascinu S Scartozzi M Labianca R | | 0，，08： | 1 |
| 14 | Dalotuzumab,a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer显示文摘 | Scartozzi M Bianconi M Maccaroni E | | 0，，3： | 1 |
| 15 | Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab- based therapy in metastatic colorectal cancer patients显示文摘 | Scartozzi M Giampieri R Maccaroni E | 2012 | Br J Cancer2012，106，5： | 1 |
| 16 | Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treat- ment in colorectal cancer patients 显示文摘 | M Scartozzi I Bearzi A Mandolesi | 2011 | Br J Cancer2011，104，： | 1 |
| 17 | Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients显示文摘 | Scartozzi M Cascinu S | 2006 | Brit J Cancer2006，95，4： | 1 |
| 18 | Gastric cancer treament : a systematic review 显示文摘 | Berardi R Scartozzi M Romagnoli E | 2004 | Oncol Rep2004，11，4： | 1 |
| 19 | Mutation of hMLH1 and hMSH2 in patient with suspected instability and abnormalities of mismatch repair protein expression显示文摘 | Scartozzi M Blanchi F Rosati S | 2002 | J Clin Oncol2002，20，： | 1 |
| 20 | Chemotherapy for advanced gastric cancer:across the year for a standard of care显示文摘 | Scartozzi M Galizia E Verdecchia L | 2007 | Expert Opin Pharmacother2007，8，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员